95 related articles for article (PubMed ID: 10832659)
1. Heparin coating of extracorporeal circuits inhibits cytokine release from mononuclear cells during cardiac operations.
Giomarelli P; Naldini A; Biagioli B; Borrelli E
Int J Artif Organs; 2000 Apr; 23(4):250-5. PubMed ID: 10832659
[TBL] [Abstract][Full Text] [Related]
2. Biocompatibility of poly2methoxyethylacrylate coating for cardiopulmonary bypass.
Noguchi M; Eishi K; Tada S; Yamachika S; Hazama S; Izumi K; Tanigawa K
Ann Thorac Cardiovasc Surg; 2003 Feb; 9(1):22-8. PubMed ID: 12667126
[TBL] [Abstract][Full Text] [Related]
3. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass.
Steinberg BM; Grossi EA; Schwartz DS; McLoughlin DE; Aguinaga M; Bizekis C; Greenwald J; Flisser A; Spencer FC; Galloway AC
Ann Thorac Surg; 1995 Sep; 60(3):525-9. PubMed ID: 7677475
[TBL] [Abstract][Full Text] [Related]
4. Heparin-coated circuits reduce myocardial injury in heart or heart-lung transplantation: a prospective, randomized study.
Wan S; LeClerc JL; Antoine M; DeSmet JM; Yim AP; Vincent JL
Ann Thorac Surg; 1999 Oct; 68(4):1230-5. PubMed ID: 10543484
[TBL] [Abstract][Full Text] [Related]
5. Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration.
Defraigne JO; Pincemail J; Larbuisson R; Blaffart F; Limet R
Ann Thorac Surg; 2000 Apr; 69(4):1084-91. PubMed ID: 10800798
[TBL] [Abstract][Full Text] [Related]
6. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits.
Kutay V; Noyan T; Ozcan S; Melek Y; Ekim H; Yakut C
J Card Surg; 2006; 21(6):572-7. PubMed ID: 17073955
[TBL] [Abstract][Full Text] [Related]
7. Active or passive bio-coating: does it matters in extracorporeal circulation?
Jacobs S; De Somer F; Vandenplas G; Van Belleghem Y; Taeymans Y; Van Nooten G
Perfusion; 2011 Nov; 26(6):496-502. PubMed ID: 21719530
[TBL] [Abstract][Full Text] [Related]
8. The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress.
Sohn N; Marcoux J; Mycyk T; Krahn J; Meng Q
Perfusion; 2009 Jul; 24(4):231-7. PubMed ID: 19858237
[TBL] [Abstract][Full Text] [Related]
9. Circulating cytokines and granulocyte-derived enzymes during complex heart surgery. A clinical study with special reference to heparin-coating of cardiopulmonary bypass circuits.
Borowiec JW; Hagman L; Tötterman TH; Pekna M; Venge P; Thelin S
Scand J Thorac Cardiovasc Surg; 1995; 29(4):167-74. PubMed ID: 8789469
[TBL] [Abstract][Full Text] [Related]
10. The impact of heparin-coated cardiopulmonary bypass circuits on pulmonary function and the release of inflammatory mediators.
de Vroege R; van Oeveren W; van Klarenbosch J; Stooker W; Huybregts MAJM; Hack CE; van Barneveld L; Eijsman L; Wildevuur CRH
Anesth Analg; 2004 Jun; 98(6):1586-1594. PubMed ID: 15155310
[TBL] [Abstract][Full Text] [Related]
11. Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin.
Harig F; Feyrer R; Mahmoud FO; Blum U; von der Emde J
Thorac Cardiovasc Surg; 1999 Apr; 47(2):111-8. PubMed ID: 10363611
[TBL] [Abstract][Full Text] [Related]
12. A prospective randomized trial comparing the clinical effectiveness and biocompatibility of heparin-coated circuits and PMEA-coated circuits in pediatric cardiopulmonary bypass.
Itoh H; Ichiba S; Ujike Y; Douguchi T; Kasahara S; Arai S; Sano S
Perfusion; 2016 Apr; 31(3):247-54. PubMed ID: 26228276
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
Gunaydin S; Farsak B; McCusker K; Vijay V; Sari T; Onur MA; Gurpinar A; Zorlutuna Y
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):135-42. PubMed ID: 19377380
[TBL] [Abstract][Full Text] [Related]
14. Deleterious effects of cardiopulmonary bypass on early graft function after single lung allotransplantation: evaluation of a heparin-coated bypass circuit.
Francalancia NA; Aeba R; Yousem SA; Griffith BP; Marrone GC
J Heart Lung Transplant; 1994; 13(3):498-507. PubMed ID: 8061027
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory response after coronary revascularization: off-pump versus on-pump (heparin-coated circuits and poly2methoxyethylacrylate-coated circuits).
Hazama S; Eishi K; Yamachika S; Noguchi M; Ariyoshi T; Takai H; Odate T; Matsukuma S; Onohara D; Yanatori M
Ann Thorac Cardiovasc Surg; 2004 Apr; 10(2):90-6. PubMed ID: 15209550
[TBL] [Abstract][Full Text] [Related]
16. Release of lipopolysaccharide toxicity-modulating proteins in patients undergoing cardiopulmonary bypass using noncoated and heparin-coated extracorporeal circuits. A clinical pilot study.
Bouma M; Maessen J; Weerwind P; Dentener M; Fransen E; de Jong D; Buurman W
Chest; 1997 Mar; 111(3):577-83. PubMed ID: 9118690
[TBL] [Abstract][Full Text] [Related]
17. PMEA coating of pump circuit and oxygenator may attenuate the early systemic inflammatory response in cardiopulmonary bypass surgery.
Ueyama K; Nishimura K; Nishina T; Nakamura T; Ikeda T; Komeda M
ASAIO J; 2004; 50(4):369-72. PubMed ID: 15307550
[TBL] [Abstract][Full Text] [Related]
18. Duroflo II heparin bonding does not attenuate cytokine release or improve pulmonary function.
Butler J; Murithi EW; Pathi VL; MacArthur KJ; Berg GA
Ann Thorac Surg; 2002 Jul; 74(1):139-42. PubMed ID: 12118746
[TBL] [Abstract][Full Text] [Related]
19. Clinical performance and biocompatibility of novel hyaluronan-based heparin-bonded extracorporeal circuits.
Gunaydin S; Mccusker K; Vijay V
J Extra Corpor Technol; 2005 Sep; 37(3):290-5. PubMed ID: 16350383
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of heparin-bonded bypass circuits related to cytokine responses in children.
Ozawa T; Yoshihara K; Koyama N; Watanabe Y; Shiono N; Takanashi Y
Ann Thorac Surg; 2000 Feb; 69(2):584-90. PubMed ID: 10735703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
